Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04458311 | Abiraterone Acetate in Combination With Tildrakizumab(ACTIon) | terminated | Phase 1 / Phase 2 | 13 | Institute of Cancer Research, United KingdomOTHER | 2 | Apr 25, 2024 | clinicaltrials |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | terminated | Phase 1 / Phase 2 | 14 | Avenge Bio, IncINDUSTRY | 1 | Apr 24, 2024 |
| NCT04633148 | Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker | terminated | Phase 1 | 16 | AvenCell Europe GmbHINDUSTRY | 1 | Apr 23, 2024 | clinicaltrials |
| NCT01393119 | Phase II, Dose Finding Study of GTx-758 | terminated | Phase 2 | 77 | GTxINDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03128294 | Long Term Survivors in Ovarian Cancer | terminated | — | 69 | University Medical Center GroningenOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05877404 | Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer | terminated | — | 112 | Wake Forest University Health SciencesOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 47 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Apr 18, 2024 | clinicaltrials |
| NCT04731441 | Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact | terminated | N/A | 12 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04677855 | Study of PCUR-101 in Combination With ADT in Patients With mCRPC | terminated | Phase 1 | 7 | Pellficure Pharmaceuticals, IncINDUSTRY | 2 | Apr 10, 2024 | clinicaltrials |
| NCT03810105 | A Study of Olaparib and Durvalumab in Prostate Cancer | terminated | Phase 2 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04743999 | Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma | terminated | Phase 2 | 9 | Henry Ford Health SystemOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT00889733 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer(OVHM-01) | terminated | Phase 1 / Phase 2 | 9 | University Health Network, TorontoOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT01962948 | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 12 | Fox Chase Cancer CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Haihe Biopharma Co., Ltd.INDUSTRY | 3 | Mar 21, 2024 | clinicaltrials |
| NCT03657108 | CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation | terminated | N/A | 6 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02574442 | Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer(Confocal) | terminated | — | 60 | British Columbia Cancer AgencyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03285841 | OCT-AF Imaging of Pre-cancers of Vulva and Cervix | terminated | — | 20 | British Columbia Cancer AgencyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b | terminated | Phase 1 | 31 | Mersana TherapeuticsINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05215496 | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer | terminated | Phase 1 | 5 | Lioe-Fee de Geus-Oei, MD PhDOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT02933801 | ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. | terminated | Phase 2 | 92 | Swiss Cancer InstituteOTHER | 4 | Mar 13, 2024 | clinicaltrials |
| NCT03533946 | Rucaparib in Nonmetastatic prOstAte With BRCAness(ROAR) | terminated | Phase 2 | 7 | University of UtahOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04718376 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer | terminated | Phase 1 | 56 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT00019695 | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05169372 | Retrospective Analysis of 68Ga-PSMA-PET in Patients With Prostate Cancer: Experience From Brazil(PET-PSMA) | terminated | — | 12 | Latin American Cooperative Oncology GroupOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03345784 | Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT04727736 | 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer | terminated | Phase 2 | 47 | Ashok MuthukrishnanOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT02279693 | Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer(PROSTRACK) | terminated | N/A | 3 | Centre Georges Francois LeclercOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT03577028 | Study of HPN424 in Patients With Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 104 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Feb 14, 2024 | clinicaltrials |
| NCT04814875 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 16 | THERAPIM PTY LTDINDUSTRY | 1 | Feb 14, 2024 | clinicaltrials |
| NCT02995330 | Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04460807 | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer(EXPERT) | terminated | Phase 3 | 23 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent(VERACITY) | terminated | Phase 3 | 105 | Veru Inc.INDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT02478502 | Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer | terminated | Phase 2 | 14 | University Hospital, AkershusOTHER | 4 | Feb 2, 2024 | clinicaltrials |
| NCT04264208 | HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer | terminated | Phase 2 | 4 | Andrei IagaruOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05673109 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 8 | Accutar Biotechnology IncINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03606486 | Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer | terminated | N/A | 52 | University of WashingtonOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05124795 | IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 18 | Immunic AGINDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04528199 | [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer | terminated | Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04864782 | QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer | terminated | Phase 2 / Phase 3 | 46 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT03858166 | Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer | terminated | Phase 4 | 68 | Shandong UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04409288 | Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer | terminated | Phase 3 | 74 | Chinese University of Hong KongOTHER | 1 | Jan 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 25, 2024source: clinicaltrials